insights_auto
Bakit bumaba ang FARN 3.92%?
Tingnan ang Higit pang Detalyechevron_right
FARN:LON
Faron Pharmaceuticals Oy
GBX 35.07
arrow_downward
-3.92%(-1.43) 1D
Okt 14, 4:30:00 PM GMT+1 · GBX
search
Lahat ng simbolo
| Simbolo | Presyo | Palitan | % ng Pagbabago |
|---|
insights_autoBumubuo ng mga nangungunang insight para sa FARN...
Buksan
GBX 36.70
Mataas
GBX 38.00
Mababa
GBX 35.07
Mkt. cap
71.19M
Avg. na dami
41.22K
Dami
10.38K
Mataas nang 52-wk
GBX 193.58
Mababa nang 52-wk
GBX 34.00
EPS
-GBX 0.10
Mga natitirang share
31.03M
Bilang ng mga empleyado
36
Buksan
GBX 36.70
Mataas
GBX 38.00
Mababa
GBX 35.07
Mkt. cap
71.19M
Avg. na dami
41.22K
Dami
10.38K
Mataas nang 52-wk
GBX 193.58
Mababa nang 52-wk
GBX 34.00
EPS
-GBX 0.10
Mga natitirang share
31.03M
Bilang ng mga empleyado
36
Mga balita at kwento
Mula sa mga source sa web at partner sa balita
investingLive
·
8 oras ang nakalipas
S&P 500 decline extends to 100 points with tech hit particularly hard
Bloomberg.com
·
5 oras ang nakalipas
S&P 500 Ends Longest Streak of Calm Since 2020 as AI Trade Sinks
Yahoo Finance
·
1 linggo ang nakalipas
These 7 major S&P 500 stocks need to rally at least 200% to reclaim their peaks
The Guardian
·
1 linggo ang nakalipas
S&P 500 and Nasdaq surge to record highs after AI chipmaker rally
Profile
Faron Pharmaceuticals is a Finnish drug discovery and development company based in Turku, Finland.
The company was founded in 2003 by a group led by Markku Jalkanen, who now acts as the company's Chief Executive Officer. It specialises in the development of treatments for acute organ traumas, vascular damage and cancer immunotherapy.
Its lead product Traumakine has been developed to treat acute respiratory distress syndrome. It is currently undergoing international phase III clinical trials after an open-label, early-phase trial showed promising results in the treatment patients with ARDS. The drug is known to function by enhancing lung CD73 expression and increasing production of anti-inflammatory adenosine, such that vascular leaking and escalation of inflammation are reduced. The U.S. Food and Drug Administration FDA has accepted the proposed protocol design for the next Traumakine study in March 2020. The phase III study is a comparison of efficacy in the treatment of patients with ARDS.
In 2020 Traumakine was selected to take part in the WHO Solidarity trial and REMAP-CAP trials to find drugs for the symptoms of Covid_19. Wikipedia
Tungkol sa Faron Pharmaceuticals Oy